Novotech, an Australia-based Asia Pacific CRO, has opened a Taiwan office as part of its ongoing Asian expansion.
Novotech has been running FDA studies in Taipei since 2008 through contract services; however, increasing demand for quality research has prompted the opening of a dedicated office to manage global and regional studies. The Taipei office will complement existing operations in India, South Korea, Thailand, Malaysia and Singapore.
Novotech CEO Alek Safarian announced the expansion at this week’s Partnerships in Clinical Trials convention in Phoenix, Ariz. He said the first Taipei office employee was hired this month and five more will be placed by mid-year.
“Like its regional neighbor South Korea, Taiwan is highly regarded by the drug development industry as a location for quality research and has a long history of global registration studies,” said Safarian.